Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5912.091 | 1.0174 | 1.0318 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5912.091 | 0.6894 | 0.4225 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5912.091 | 0.0176 | -0.9507 | 1.0917 | |
| CAMA-1 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5912.091 | 0.0084 | -0.9748 | 1.0917 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7429.09 | 1.0076 | 1.0067 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7429.09 | 1.0246 | 1.0218 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7429.09 | 1.0099 | 1.0088 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7429.09 | 1.0167 | 1.0148 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7429.09 | 1.0442 | 1.0389 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7429.09 | 1.0541 | 1.0475 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7429.09 | 0.6987 | 0.7048 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7429.09 | 0.0091 | -0.7538 | 2.2456 | |
| HBL-100 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7429.09 | 0.0068 | -0.7829 | 2.2456 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7430.091 | 0.9282 | 0.9174 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7430.091 | 1.0435 | 1.0488 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7430.091 | 0.9855 | 0.9836 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7430.091 | 0.9986 | 0.9984 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7430.091 | 1.0305 | 1.0343 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7430.091 | 0.9789 | 0.9760 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7430.091 | 0.7599 | 0.7122 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7430.091 | 0.0097 | -0.8548 | 1.7667 | |
| HCC1143 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7430.091 | 0.0044 | -0.9077 | 1.7667 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7431.092 | 0.9717 | 0.9621 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7431.092 | 0.9530 | 0.9368 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7431.092 | 0.9585 | 0.9443 | 1.5006 |